This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
Carbamylated serum albumin as a risk factor for mortality in end-stage renal disease (ESRD)	<p>Carbamylated serum albumin could be a useful marker of increased mortality risk in patients with ESRD. In two cohorts totaling 1,348 patients with ESRD, a higher percentage of carbamylated serum albumin was associated with a higher risk of death. Next steps could include determining if reducing the levels of carbamylated serum albumin helps lower mortality in animal models for ESRD.</p> <p>SciBX 6(11); doi:10.1038/scibx.2013.276 Published online March 21, 2013</p>	Patent and licensing status unavailable	<p>Berg, A.H. <i>et al. Sci. Transl. Med.</i>; published online March 6, 2013; doi:10.1126/scitranslmed.3005218 Contact: Anders H. Berg, Beth Israel Deaconess Medical Center, Boston, Mass. e-mail: ahberg@bidmc.harvard.edu</p>